ECSP013979A - Formulación de tabletas de oxazolidinona - Google Patents

Formulación de tabletas de oxazolidinona

Info

Publication number
ECSP013979A
ECSP013979A EC2001003979A ECSP013979A ECSP013979A EC SP013979 A ECSP013979 A EC SP013979A EC 2001003979 A EC2001003979 A EC 2001003979A EC SP013979 A ECSP013979 A EC SP013979A EC SP013979 A ECSP013979 A EC SP013979A
Authority
EC
Ecuador
Prior art keywords
oxazolidinone
tablets
formulation
provides
antibacterial agent
Prior art date
Application number
EC2001003979A
Other languages
English (en)
Inventor
Homer Lin
Ken Yamamoto
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22703542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP013979(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of ECSP013979A publication Critical patent/ECSP013979A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La presente invención proporciona una tableta comprimida de un agente antibacteriano de oxazolidinona que provee una alta carga de fármaco y una excelente biodisponibilidad.
EC2001003979A 2000-03-22 2001-03-22 Formulación de tabletas de oxazolidinona ECSP013979A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19096900P 2000-03-22 2000-03-22

Publications (1)

Publication Number Publication Date
ECSP013979A true ECSP013979A (es) 2002-01-25

Family

ID=22703542

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001003979A ECSP013979A (es) 2000-03-22 2001-03-22 Formulación de tabletas de oxazolidinona

Country Status (33)

Country Link
EP (1) EP1265608B1 (es)
JP (1) JP2003527424A (es)
KR (2) KR20070094673A (es)
CN (1) CN1208058C (es)
AR (1) AR033357A1 (es)
AT (1) ATE412413T1 (es)
AU (2) AU2001243243B2 (es)
BG (1) BG107117A (es)
BR (1) BR0108846A (es)
CA (1) CA2400118A1 (es)
CZ (1) CZ20023133A3 (es)
DE (1) DE60136341D1 (es)
DK (1) DK1265608T3 (es)
EA (1) EA006772B1 (es)
EC (1) ECSP013979A (es)
ES (1) ES2312422T3 (es)
HK (1) HK1054325B (es)
HR (1) HRP20020765A2 (es)
HU (1) HUP0300378A3 (es)
IL (1) IL151788A0 (es)
MX (1) MXPA02009316A (es)
MY (1) MY136370A (es)
NO (1) NO20024505L (es)
NZ (1) NZ521525A (es)
PE (2) PE20011126A1 (es)
PL (1) PL201686B1 (es)
PT (1) PT1265608E (es)
SK (1) SK12092002A3 (es)
TW (1) TWI293028B (es)
UA (1) UA77654C2 (es)
WO (1) WO2001070225A2 (es)
YU (1) YU69802A (es)
ZA (1) ZA200207073B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
PT1749517E (pt) * 2005-07-20 2008-09-29 Teva Pharma Composição farmacêutica estável compreendendo a forma iv de linezolida
WO2010026597A1 (en) * 2008-09-02 2010-03-11 Hetero Research Foundation Oral dosage forms of linezolid and processes for their preparation
ES2836809T3 (es) * 2010-11-24 2021-06-28 Melinta Subsidiary Corp Composiciones farmacéuticas
WO2013088389A1 (en) * 2011-12-14 2013-06-20 Alembic Pharmaceuticals Limited Linezolid premix
CN103505459B (zh) * 2012-06-20 2016-02-24 北京万生药业有限责任公司 利奈唑胺药物组合物
CN104622831B (zh) * 2013-11-06 2018-06-22 江苏豪森药业集团有限公司 一种口服片剂及其制备方法
LT3277270T (lt) * 2015-04-01 2022-01-10 Akebia Therapeutics, Inc. Kompozicijos ir būdai skirti anemijos gydymui
CN106727396A (zh) * 2016-11-22 2017-05-31 湖北广济药业股份有限公司 一种ⅱ晶型利奈唑胺片及其制备方法
CN109481412A (zh) * 2018-08-17 2019-03-19 扬子江药业集团北京海燕药业有限公司 一种ii晶型利奈唑胺片及其制备工艺

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993767A (en) * 1975-11-18 1976-11-23 A. H. Robins Company, Incorporated Compositions to suppress gastric bleeding in indomethacin and phenylbutazone therapy
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
CN1142162C (zh) * 1999-05-27 2004-03-17 法玛西雅厄普约翰美国公司 作为抗菌剂的新的双环噁唑烷酮

Also Published As

Publication number Publication date
ES2312422T3 (es) 2009-03-01
DK1265608T3 (da) 2008-12-08
PE20020499Z (es) 2002-07-12
TWI293028B (en) 2008-02-01
HUP0300378A3 (en) 2004-11-29
CA2400118A1 (en) 2001-09-27
KR20070094673A (ko) 2007-09-20
HRP20020765A2 (en) 2003-12-31
DE60136341D1 (de) 2008-12-11
ATE412413T1 (de) 2008-11-15
HK1054325B (zh) 2006-01-13
IL151788A0 (en) 2003-04-10
AU2001243243B2 (en) 2004-10-14
PE20011126A1 (es) 2001-10-31
HUP0300378A2 (hu) 2003-06-28
SK12092002A3 (sk) 2002-12-03
NO20024505D0 (no) 2002-09-20
YU69802A (sh) 2005-11-28
EP1265608B1 (en) 2008-10-29
CN1418097A (zh) 2003-05-14
PL366067A1 (en) 2005-01-24
PT1265608E (pt) 2008-12-15
CN1208058C (zh) 2005-06-29
EP1265608A2 (en) 2002-12-18
KR20020083185A (ko) 2002-11-01
BR0108846A (pt) 2003-05-06
UA77654C2 (en) 2007-01-15
KR100786410B1 (ko) 2007-12-17
WO2001070225A3 (en) 2001-12-13
NZ521525A (en) 2004-02-27
WO2001070225A2 (en) 2001-09-27
NO20024505L (no) 2002-09-20
AU4324301A (en) 2001-10-03
JP2003527424A (ja) 2003-09-16
EA006772B1 (ru) 2006-04-28
AR033357A1 (es) 2003-12-17
EA200201006A1 (ru) 2003-02-27
CZ20023133A3 (cs) 2003-01-15
MY136370A (en) 2008-09-30
PL201686B1 (pl) 2009-04-30
HK1054325A1 (en) 2003-11-28
MXPA02009316A (es) 2004-04-05
BG107117A (bg) 2003-05-30
ZA200207073B (en) 2003-12-03

Similar Documents

Publication Publication Date Title
DOP2019000185A (es) Una formulación sólida de dosificación farmacéutica
HUP0500509A2 (hu) Azonnali felszabadulást biztosító mikronizált gyógyászati és gyógytáp porok
UY28281A1 (es) Productos farmacéuticos
DE60326709D1 (de) Pharmazeutische formulierungen mit verbesserter bioverfügbarkeit
CR9767A (es) COMPOSICION QUE COMPRENDE UN INHIBIDOR DE LA ABSORCION DEL COLESTEROL UN INHIBIDOR DE LA HMG-COA Y UN AGENTE ESTABILIZADOR Solicitud divisional 7658
PE20000559A1 (es) Formulacion de tabletas comprimidas de efavirenz
ATE331537T1 (de) Topisch anwendbare arzneimittelformulierung
ECSP013979A (es) Formulación de tabletas de oxazolidinona
AR034517A1 (es) Formulacion farmaceutica
MXPA02012160A (es) Composiciones medicinales las cuales contienen derivados de propenona.
AR033467A1 (es) Comprimido de meloxicam de rapida disgregacion
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
HUP0303860A3 (en) A pharmaceutical tablet having a high active ingredient
DE60111503D1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
HRPK20030766B3 (en) Combination of a taxane and cyclin-dependent kinase inhibitor
AU2001212552A1 (en) Pharmaceutical disinfectants comprising usnic and essential oils
CA2473718A1 (en) Immediate-release pharmaceutical dosage form comprising polymorphous tibolone
UY27170A1 (es) Formulación de medicamento que contiene un agente agonista muscarínico
ATE331509T1 (de) Zusammensetzung die paracetamol und niflumic säure enthält
DE50006408D1 (de) Pharmazeutische zubereitung enthaltend dithranol
PT102453B (pt) Formulacao de um composto cefalosporinico e estojo compreendendo o referido composto e uma solucao aquosa tamponada
UY27345A1 (es) Formulación farmacéutica.